Literature DB >> 686155

Experimental Acanthamoeba infections in mice pretreated with methylprednisolone or tetracycline.

S M Markowitz, T Sobieski, A J Martinez, R J Duma.   

Abstract

Human infections due to free-living amebas of the genus Acathamoeba have been reported sporadically, occasionally in individuals with underlying diseases. To determine if such infections may be considered opportunistic, groups of laboratory mice were pretreated with either methylprednisolone or tetracycline and inoculated intranasally with 1.075 times 10(4) Acanthamoeba castellanii isolated from a natural fresh water well. Results were compared with controls receiving either drug or amebas alone and with controls receiving saline injections with and without amebas. The mortality rate for those animals receiving methylprednisolone and amebas (50%) was found to be greater than the mortality in ameba controls (10%) (P equal 0.074). Similarly, the mortality rate for animals receiving tetracycline and amebas (60%) was higher than the mortality in the ameba controls (10%) (P equal 0.0286). Precise mechanisms for the increased mortality were unknown but were suspected to be due to the capacity of either corticosteroids or tetracycline to suppress host defenses, particularly those depending on neutrophils. The findings suggest a potentially pathogenic role for naturally occurring Acanthamoeba sp in humans with depressed host immunity.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 686155      PMCID: PMC2018276     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  31 in total

1.  Fatal amebiasis complicating corticosteroid management of pemphigus vulgaris.

Authors:  J EISERT; J E HANNIBAL; S L SANDERS
Journal:  N Engl J Med       Date:  1959-10-22       Impact factor: 91.245

2.  Experimental infection of mice and monkeys by Acanthamoeba.

Authors:  C G CULBERTSON; J W SMITH; H K COHEN; J R MINNER
Journal:  Am J Pathol       Date:  1959 Jan-Feb       Impact factor: 4.307

3.  Effects of ACTH on induced malaria in man.

Authors:  E H KASS; Q M GEIMAN; M FINLAND
Journal:  N Engl J Med       Date:  1951-12-27       Impact factor: 91.245

4.  Inhibition of phagocytosis by aureomycin.

Authors:  J MUNOZ; R GEISTER
Journal:  Proc Soc Exp Biol Med       Date:  1950-11

5.  Brain abscesses caused by free-living amoeba probably of the genus Hartmannella in a patient with Hodgkin's disease.

Authors:  B V Jager; W P Stamm
Journal:  Lancet       Date:  1972-12-23       Impact factor: 79.321

6.  Cellular immunity after intravenous administration of methylprednisolone.

Authors:  M L Webel; R E Ritts; H F Taswell; J V Danadio; J E Woods
Journal:  J Lab Clin Med       Date:  1974-03

7.  Amoebic infection of the eye.

Authors:  J Naginton; P G Watson; T J Playfair; J McGill; B R Jones; A D Steele
Journal:  Lancet       Date:  1974-12-28       Impact factor: 79.321

8.  Experimental pneumonitis and encephalitis caused by acanthamoeba in mice: pathogenesis and ultrastructural features.

Authors:  A J Martinez; S M Markowitz; R J Duma
Journal:  J Infect Dis       Date:  1975-06       Impact factor: 5.226

9.  Meningoencephalitis and brain abscess due to a free-living amoeba.

Authors:  R J Duma; W B Helwig; A J Martinez
Journal:  Ann Intern Med       Date:  1978-04       Impact factor: 25.391

10.  The in vitro action of hydrocortisone on leucocyte migration.

Authors:  M M KETCHEL; C B FAVOUR; S H STURGIS
Journal:  J Exp Med       Date:  1958-02-01       Impact factor: 14.307

View more
  12 in total

1.  Tigecycline inhibits proliferation of Acanthamoeba castellanii.

Authors:  Bijay Kumar Jha; Incheol Seo; Hyun-Hee Kong; Seong-Il Suh; Min-Ho Suh; Won-Ki Baek
Journal:  Parasitol Res       Date:  2015-01-07       Impact factor: 2.289

2.  Immunity to pathogenic free-living amoebae: role of cell-mediated immunity.

Authors:  R T Cursons; T J Brown; E A Keys; K M Moriarty; D Till
Journal:  Infect Immun       Date:  1980-08       Impact factor: 3.441

3.  Neurotrophic Factors in Experimental Cerebral Acanthamoebiasis.

Authors:  Natalia Łanocha-Arendarczyk; Karolina Kot; Irena Baranowska-Bosiacka; Patrycja Kapczuk; Aleksandra Łanocha; Danuta Izabela Kosik-Bogacka
Journal:  Int J Mol Sci       Date:  2022-04-29       Impact factor: 6.208

4.  Acanthamoeba produces disseminated infection in locusts and traverses the locust blood-brain barrier to invade the central nervous system.

Authors:  Parisa N Mortazavi; Graham Goldsworthy; Ruth Kirk; Naveed A Khan
Journal:  BMC Microbiol       Date:  2010-07-08       Impact factor: 3.605

5.  Subacute and chronic meningoencephalitis in mice after experimental infection with a strain of Naegleria fowleri originally isolated from a patient.

Authors:  S Dempe; A J Martinez; K Janitschke
Journal:  Infection       Date:  1982-01       Impact factor: 3.553

Review 6.  Acanthamoeba spp. as agents of disease in humans.

Authors:  Francine Marciano-Cabral; Guy Cabral
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

7.  Granulomatous amebic encephalitis presenting as a cerebral mass lesion.

Authors:  A J Martínez; C A García; M Halks-Miller; R Arce-Vela
Journal:  Acta Neuropathol       Date:  1980       Impact factor: 17.088

8.  Predisposing factors in Pneumocystis carinii pneumonia: effects of tetracycline, protein malnutrition, and corticosteroids on hosts.

Authors:  P D Walzer; M LaBine; T J Redington; M T Cushion
Journal:  Infect Immun       Date:  1984-12       Impact factor: 3.441

9.  Granulomatous encephalitis, intracranial arteritis, and mycotic aneurysm due to a free-living ameba.

Authors:  A J Martínez; C Sotelo-Avila; H Alcalá; E Willaert
Journal:  Acta Neuropathol       Date:  1980       Impact factor: 17.088

10.  Expression and Activity of COX-1 and COX-2 in Acanthamoeba sp.-Infected Lungs According to the Host Immunological Status.

Authors:  Natalia Łanocha-Arendarczyk; Irena Baranowska-Bosiacka; Karolina Kot; Izabela Gutowska; Agnieszka Kolasa-Wołosiuk; Dariusz Chlubek; Danuta Kosik-Bogacka
Journal:  Int J Mol Sci       Date:  2018-01-02       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.